The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand. The main question the study aims to answer is: What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.
This study is a cross-sectional study. Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC). GINA and ACT are questionnaires used to assess the level of asthma control.
Study Type
OBSERVATIONAL
Enrollment
289
GINA and ACT are questionnaires used to assess the level of asthma control.
Spirometry is a tool used to assess pulmonary function.
FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
Faculty of Medicine, Thammasat University
Pathum Thani, Thailand
Prevalence rate of mild-to-moderate asthma remission
Prevalence rate of mild-to-moderate asthma remission (%)
Time frame: An average of 1 year
Asthma control in patients with mild-to-moderate asthma
Rate of patients with well-controlled asthma. Well-controlled asthma is defined as an Asthma Control Test (ACT) score of 20 or higher.
Time frame: At baseline and at 12 months
Airway obstruction in patients with mild-to-moderate asthma
Airway obstruction is assessed using FEV1/FVC ratio on spirometry.
Time frame: At baseline and at 12 months
Severity of aiway obstruction in patients with mild-to-moderate asthma
The severity of aiway obstruction is assessed using FEV1 % predicted on spirometry.
Time frame: At baseline and at 12 months
Eosinophil airway inflammation in patients with mild-to-moderate asthma
Eosinophil airway inflammation is assessed using blood eosinophil count (cells/µL).
Time frame: At baseline and at 12 months
Type 2 airway inflammation in patients with mild-to-moderate asthma
Type 2 airway inflammation is assessed using fractional exhaled nitric oxide (FeNO, ppb).
Time frame: At baseline and at 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
BEC is a tool used to assess eosinophilic inflammation and asthma remission.